Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Lowering 3α,5α-THP in the hippocampus increases anxiety and depression in proestrous rats.

Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.

In this study, bromocriptine's inhibition of prolactin promoted secondary follicle development during anagen in cashmere goats, likely via changes in specific gene expressions, despite not affecting fiber characteristics or primary follicle activity.

This article reviews the potential neuroprotective effects of 17α‐estradiol in neurodegenerative diseases and highlights its possibly lower toxicity compared to more feminizing hormones, but it reports no new clinical findings.

This study found no significant difference in the severity of alopecia areata between treatments with platelet-rich plasma and triamcinolone acetonide; further high-quality trials of PRP are needed.

This study reports that progesterone metabolism to DHP and THP is necessary for its neuroprotective effect against kainic acid excitotoxicity in ovariectomized rats, unlike the synthetic progestin MPA.

This study found that the novel IPC analog SIG-1451 may inhibit inflammatory cytokine release in cell-based assays relevant to allergic dermatitis.

This study found no significant difference in estrogen and progesterone receptor expression between androgenic alopecia and alopecia areata, suggesting an indirect hormonal influence on androgenic alopecia.

This study found that several synthesized compounds were potent inhibitors of human steroid 5alpha-reductase type 2 and reduced prostate weights in treated rats, with compound 15 showing promise for potency in humans.

This study found that newly synthesized steroidal trienones demonstrated stronger 5α-reductase inhibitory activity compared to dienones in various biological models, suggesting potential for developing enhanced antiandrogenic drugs.

This study found that deoxycorticosterone-derived neurosteroids modulate GABA A receptor function and may influence stress-induced changes in seizure susceptibility by elevating seizure thresholds in animal models.

Nanocrystals improve alopecia areata treatment by better targeting hair follicles.

This article discusses oral spironolactone therapy for female patients with acne, hirsutism, or androgenic alopecia and reports no new clinical results.

This study found that low-dose methotrexate significantly reduced the steroid requirement in subjects with corticosteroid-requiring asthma without altering their clinical status or causing significant complications.

This study introduces a novel pro-drug formulation of all-trans retinoic acid that reduces skin inflammation and achieves sustained drug release over several days compared to traditional methods.

This research outlines a chemical synthesis process for Finasteride, detailing the conversion of pregnadienolone acetate through various chemical reactions and modifications.

This study found that the synthesized compound 7b exhibited higher 5α-reductase inhibitory activity, increased solubility, and dissolution compared to finasteride, suggesting its potential as a lead compound for benign prostatic hyperplasia treatment.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.

In this study, researchers found that during late pregnancy, neuroactive steroid fluctuations increase the number of extrasynaptic GABAA receptors in rat hippocampal cells.

In this case study, an 11-year-old boy with extensive alopecia areata showed 80% hair regrowth after six months of treatment with methylprednisolone despite initial lack of response to topical therapies.

This study reports that RU 58841-myristate, a new antiandrogen prodrug formulated with solid lipid nanoparticles, shows potential for targeting hair follicles in preclinical laboratory settings.

This study found that the dehydroepiandrosterone hydroxylating enzyme system in hair follicles is similar to the liver monooxygenase system, sharing characteristics such as inhibition by carbon monoxide and dependency on NADPH.

This study found that platelet-rich plasma may be an effective adjuvant treatment for androgenetic alopecia, especially when combined with antiandrogenetic medications and topical minoxidil, though factors like patient age and family history could influence outcomes.

This case study reports an Asian female with congenital adrenal hyperplasia presenting atypically with polymenorrhagia, who showed improvement with oral dexamethasone, despite no change in hirsutism or clitoromegaly.

This study describes the synthesis of finasteride from 4-androstene-3,17-dione in a seven-step process with an overall yield of 18.6%.

This case report discusses the use of a prostaglandin analogue for treating eyebrow loss in a patient with frontal fibrosing alopecia, but provides no new clinical results.

This study found that CPA-loaded nanoparticles, particularly SLN formulations, increased CPA epidermal penetration compared to a conventional cream and may reduce side effects in treating androgen-dependent conditions.

This article reviews the clinical characterization and potential treatments for androgenetic alopecia, highlighting minoxidil's efficacy in hair regrowth and noting the need for further genetic research; it reports no new clinical results.

In this study, researchers found that petroleum ether extract of Eclipta alba significantly stimulated follicular keratinocyte proliferation and reduced TGF-β1 expression in nude mice, suggesting potential use for certain types of alopecia.